Nadja Blagitko‐Dorfs

Author

University of Freiburg

Also Known As

Nadja Blagitko-Dorfs, Nadja Blagitko‐Dorfs

Publications

633

Citations

H-Index

Concepts

All Affiliations

University of Freiburg University Medical Center Freiburg German Cancer Research Center Heidelberg University Kyoto University

About

Nadja Blagitko‐Dorfs is an author at University of Freiburg specializing in medicine, cell biology, and epigenetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	378
2	Cell Biology	4	4	318
3	Engineering	1	1	36
4	Health Sciences	1	1	108
5	Biochemistry	1	1	36

Nadja Blagitko‐Dorfs

Publications

556

Citations

H-Index

Page 1

	Year	Citations
The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells Maika Almstedt, Nadja Blagitko‐Dorfs, Jesús Duque‐Afonso, Leukemia Research Hematological MalignancyTumor BiologyMyeloid Leukemia CellsMedicineImmunology	2010	166
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation Nadja Blagitko‐Dorfs, Pascal Schlosser, Gabriele Greve, Leukemia Hematological MalignancyHdac InhibitorsMixed-phenotype Acute LeukemiaGene Body DemethylationMalignant Blood Disorder	2018	108
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy Pragya Srivastava, Benjamin E. Paluch, Junko Matsuzaki, Oncotarget	2016	68
Quantitative analyses of <i>DAPK1</i> methylation in AML and MDS Rainer Claus, Björn Hackanson, Anna R. Poetsch, International Journal of Cancer EngineeringEpigenetic ChangeMixed-phenotype Acute LeukemiaAberrant Dna MethylationPathology	2011	36
Psychophysiological insomnia and respiratory tract infections: results of an infection-diary-based cohort study Alexandra Nieters, Nadja Blagitko‐Dorfs, Hans‐Hartmut Peter, SLEEP	2019	29
Tracing the development of acute myeloid leukemia in CBL syndrome Heiko Becker, Kenichi Yoshida, Nadja Blagitko‐Dorfs, Blood	2014	28
Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat Nadja Blagitko‐Dorfs, Yi Jiang, Jesús Duque‐Afonso, PLoS ONE Mixed-phenotype Acute LeukemiaGeneticsEpigenetic ChangeRetinoic AcidCancer Biology	2013	28
Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells Simin Öz, Günter Raddatz, Maria Rius, Nucleic Acids Research	2014	28
Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients Julia Stomper, Ruth Meier, Tobias Ma, Clinical Epigenetics	2021	25
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy Jan K. Hiller, Claudia Schmoor, Verena I. Gaidzik, Annals of Hematology Hematological MalignancyChromatinOncologyEpigenetic AberrationsEpigenetic Change	2017	24

Page 1